Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2020-09-28 Capital/Financing Update
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated September 28, 2020. It is a preliminary prospectus related to an offering of units consisting of common stock and warrants. The text includes detailed information about the offering, underwriting, risk factors, management discussion, and financial statements index. Form S-1 is a registration statement used for initial public offerings or other securities offerings and is not a financial report, earnings release, or management report. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high due to the clear identification of the form and content.
2020-09-28 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 14, 2020. It details an equity distribution agreement and an increase in the market offering under a Sales Agreement, including the sale of additional shares of common stock. The content focuses on capital raising activities and updates related to financing. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is not a proxy, earnings release, or management discussion. It is a regulatory filing reporting a material event related to capital structure and financing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2020-07-14 English
425B5
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement No. 3' and relates to the issuance and sale of common stock under an 'at-the-market' offering program. It references a Sales Agreement and details about the offering price, shares, and sales agent. The document is a prospectus supplement, which is a type of capital raising disclosure document. It is not an annual report, earnings release, or any other type of report. It is specifically about financing activities and capital structure changes. The document length is 3751 characters, which is relatively short but contains substantive information about a capital raising event. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP).
2020-07-14 English
FORM 10-Q
Interim / Quarterly Report Q3 2020
2020-07-13 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes the execution of a Project Invention Exercise Notice related to licensing intellectual property rights, which is an event disclosure rather than a financial report or earnings release. The document length is 3472 characters, which is relatively short and does not contain financial statements or detailed financial analysis. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. It is also not a proxy statement, voting results, or a director dealing report. The nature of the filing fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2020-06-26 English
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the securities to be registered, incorporation by reference of prior filings, and signatures. It is not a financial report, earnings release, or management discussion, but rather a capital market filing related to share issuance under an equity incentive plan. This fits the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is SHA with high confidence.
2020-06-25 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.